Nephrology Dialysis Transplantation Role of polyol pathway in nonenzymatic glycation

In order to confirm the link between nonenzymatic glycation and the polyol pathway, we observed the effect of treatment with epalrestat (Ep), an aldose reductase inhibitor, on the concentration of advanced glycation end-products (AGEs) in erythrocytes from diabetic patients. We also examined the effect of the drug on erythrocyte fructose 3-phosphate (F3P), a novel metabolite that has been reported to relate to the polyol pathway, and ascertained the glycation capability of F3P and its possible breakdown product, 3-deoxyglucosone (3DG), by incubating the metabolites with bovine serum albumin (BSA). Incubation of BSA with F3P or 3DG resulted in a greater production of AGEs in comparison with the incubation with glucose or fructose. F3P was significantly increased in erythrocytes from diabetic patients compared with those from nondiabetic individuals and was lower in patients who had been treated with Ep than in those who were free from the compound. A treatment of patients with Ep for 1 month resulted in a significant decrease in F3P. Erythrocyte AGEs were significantly elevated in diabetic patients compared with nondiabetic individuals and tended to be lower in patients taking Ep than in those without Ep. Administration of Ep for 2 months decreased AGEs. These results show that the polyol pathway is likely to play a substantial role in the nonenzymatic glycation of proteins and the suppression of E3P as well as AGEs by an aldose reductase inhibitor may explain in part the preventive effect of the drug on diabetic complications.

[1]  M. Oka,et al.  Aldose Reductase Inhibitors , 2001, Journal of enzyme inhibition.

[2]  M. Cotter,et al.  The relationship of vascular changes to metabolic factors in diabetes mellitus and their role in the development of peripheral nerve complications. , 1994, Diabetes/metabolism reviews.

[3]  J. Nyengaard,et al.  Hyperglycemic Pseudohypoxia and Diabetic Complications , 1993, Diabetes.

[4]  T. Brown,et al.  Detection of fructose-3-phosphokinase activity in intact mammalian lenses by 31P NMR spectroscopy. , 1993, The Journal of biological chemistry.

[5]  M. Brownlee,et al.  Glycation Products and the Pathogenesis of Diabetic Complications , 1992, Diabetes Care.

[6]  T. Brown,et al.  Fructose metabolism in the human erythrocyte. Phosphorylation to fructose 3-phosphate. , 1992, The Biochemical journal.

[7]  S. Yagihashi,et al.  Effect of Aminoguanidine on Functional and Structural Abnormalities in Peripheral Nerve of STZ-Induced Diabetic Rats , 1992, Diabetes.

[8]  H. Hammes,et al.  Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[9]  G. Jerums,et al.  Retardation by Aminoguanidine of Development of Albuminuria, Mesangial Expansion, and Tissue Fluorescence in Streptozocin-Induced Diabetic Rat , 1991, Diabetes.

[10]  Y. Morino,et al.  Immunochemical approach to characterize advanced glycation end products of the Maillard reaction. Evidence for the presence of a common structure. , 1991, The Journal of biological chemistry.

[11]  T. Brown,et al.  Identification of sorbitol 3-phosphate and fructose 3-phosphate in normal and diabetic human erythrocytes. , 1990, The Journal of biological chemistry.

[12]  T. Brown,et al.  Identification of fructose 3-phosphate in the lens of diabetic rats. , 1990, Science.

[13]  A. Oronsky,et al.  Administration of an aldose reductase inhibitor induces a decrease of collagen fluorescence in diabetic rats. , 1988, The Journal of clinical investigation.

[14]  P. Raskin,et al.  Aldose reductase inhibitors and diabetic complications. , 1987, The American journal of medicine.

[15]  D. Greene,et al.  Sorbitol, phosphoinositides, and sodium-potassium-ATPase in the pathogenesis of diabetic complications. , 1987, The New England journal of medicine.

[16]  N. Hotta,et al.  Effects of a fructose-rich diet and the aldose reductase inhibitor, ONO-2235, on the development of diabetic neuropathy in streptozotocin-treated rats , 1985, Diabetologia.

[17]  A. Cerami,et al.  Nonenzymatic glycosylation and the pathogenesis of diabetic complications. , 1984, Annals of internal medicine.

[18]  J. Kinoshita,et al.  Osmotic Changes caused by the Accumulation of Dulcitol in the Lenses of Rats fed with Galactose , 1962, Nature.

[19]  H. Kato,et al.  3-Deoxyglucosone, an intermediate product of the Maillard reaction. , 1989, Progress in clinical and biological research.